We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Improving on "Natural" Rodent Antibodies
-
1. The immunogenicity problem in antibody therapy
- Prof. Herman Waldmann
-
2. Antibodies by protein engineering
- Prof. Sir Gregory Winter
-
3. The generation of diversity in antibody genes
- Prof. Michael Neuberger
-
4. Innate immunity to retroelements by human AID/APOBEC3 proteins
- Prof. Reuben Harris
-
5. Fc receptors and antibody effector functions
- Dr. Mike Clark
-
6. Antibody engineering of Fc effector functions
- Dr. Mike Clark
-
7. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
- Antibodies in Cancer Therapy
-
8. Monoclonal antibodies and the ErbB system in human cancer
- Prof. Mark Greene
-
9. Checkpoint blockade in cancer immunotherapy
- Prof. James Allison
-
10. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
- Diagnostic Antibodies
-
11. Monitoring therapy with antibodies
- Dr. Geoffrey Hale
- Cell Surface Glycoproteins on Cells of the Immune System
-
12. Cell surface glycoproteins on cells of the immune system
- Prof. Neil Barclay
- Antibodies as Immunosuppressants
-
13. Monoclonal antibodies to induce therapeutic immunological tolerance
- Prof. Herman Waldmann
-
14. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
15. Antibody therapy of multiple sclerosis
- Dr. Alasdair Coles
- Prof. Alastair Compston
-
16. Monoclonal antibodies in the management of rheumatoid arthritis
- Prof. John Isaacs
- Archived Lectures *These may not cover the latest advances in the field
-
19. Alemtuzumab (Campath-1H) in therapy of CLL
- Prof. Kanti Rai
-
20. VEGF inhibitors for anti-angiogenic therapy
- Prof. Kari Alitalo
- Dr. Bronislaw Pytowski
-
21. Human antibodies produced in mice
- Dr. Marianne Bruggemann
-
22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man
- Prof. Christian Larsen
-
23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity
- Prof. Thomas Tedder
-
24. Anti-IL-2 receptor antibodies as models for cancer therapy
- Prof. Thomas Waldmann
-
25. Anti TNF therapy in rheumatoid arthritis
- Prof. Marc Feldmann
-
26. Novel immunotherapeutic proteins: immunoligand
- Prof. Terry Strom
-
27. Diagnostic immunohistopathology
- Prof. David Mason
-
28. Antibodies in the control of type I diabetes
- Prof. Lucienne Chatenoud
-
29. The challenge of targeting toxins to tumors
- Prof. Ben Seon
-
30. Antibody depletion therapy in transplantation: implications for tolerance
- Prof. Laurence Turka
-
31. Antibodies as anti-virals
- Prof. Dennis Burton
Printable Handouts
Navigable Slide Index
- Introduction
- History of insulin-dependent dabetes mellitus
- Autoimmune origin of human type 1 diabetes
- Islet cells autoantibodies
- Multiplicity of autoantigens in IDDM
- An experimental model - NOD mouse
- Natural history of type 1 diabetes
- The transfer of diabetes
- Insulitis transfer with purified T-cell subsets
- Regulatory T-cells in a diabetes co-transfer model
- Prevention of diabetes transfer by TREG
- Objectives of immunotherapy in IDDM
- Three features of immunotherapy of diabetes
- Trial of CsA in recently diagnosted IDDM
- Immunosuppression vs. immune tolerance
- Back to NOD mouse model
- The CD3 molecular complex
- Diabetes remission in CD3 antibody-treated mice
- CD3 antibody-treated NOD mice
- Increased T-cells in anti-CD3 treated mice
- Effect of anti-TGFbeta on remissions
- Antibodies used in clinical trials
- Non-mitogenic CD3 antibody treatments
- The ChAglyCD3 antibody
- Efficacy measurements
- ChAglyCD3 antibody treatment: results
- Insulin needs at 18 months
- Proportions of circulating lymphocytes
- EBV reactivation
- Representative data from three patients
- CD8 T-cell response to EBV lytic antigens
- Conclusions
- Acknowledgments
Topics Covered
- The history of IDDM
- Autoimmune origin of human type 1 diabetes
- Natural history and pathophysiology of type 1 diabetes
- The role of regulatory T-cells in the control of type 1 diabetes
- Objectives of immunotherapy in insulin-dependent diabetes mellitus
- The use of immunosuppressants in type 1 diabetes
- The use of tolerance promoting monoclonal antibodies in type 1 diabetes: the case of CD3 antibodies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Chatenoud, L. (2019, June 13). Antibodies in the control of type I diabetes [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 5, 2025, from https://doi.org/10.69645/XLYJ6327.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Lucienne Chatenoud has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.